The Institute of Clinical and Economic Review (ICER) found the medicines dupilumab and crisaborole to offer effective long-term treatment of atopic dermatitis, also known as eczema. A portion of the press release is below.
Boston, Mass., June 8, 2017 – The Institute of Clinical and Economic Review (ICER) has issued a Final Evidence Report that concludes that dupilumab (Dupixent®, Regeneron and Sanofi) offers good long-term value for patients with moderate-to-severe atopic dermatitis.
The report, along with an accompanying Report-at-a-Glance, also assesses the comparative clinical effectiveness of crisaborole (Eucrisa™, Pfizer) for mild-to-moderate disease.
"Our analyses showed that dupilumab offers important clinical benefit for patients with moderate-to-severe atopic dermatitis. Moreover, the drug was priced in a way that aligns well with the benefit it provides to patients," noted David Rind, MD, MSc, ICER's Chief Medical Officer.
"We hope our report and recommendations can be a starting point for conversations among patient groups, payers, clinicians, and manufacturers, especially related to potential challenges with affordability, to ensure that those patients who can benefit from treatment with dupilumab are able to access it."